AHEAD 3-45 Study
Thank you for your interest in the AHEAD 3-45 Study!
AHEAD 3-45 is a global multicenter clinical trial aimed at preventing memory loss due to Alzheimer's disease, designed and conducted by the Alzheimer's Clinical Trials Consortium (ACTC) in collaboration with Eisai. Funding is through a public-private partnership with National Institute on Aging (NIH), Eisai, and several philanthropic organizations.
AHEAD 3-45 combines two studies with distinct participant groups but with common screening and recruitment to increase efficiency. More details on each study are below.
We anticipate enrollment for AHEAD 3-45 to begin in the first half of 2020. One way to take steps toward participating in AHEAD 3-45, is to enroll in the Alzheimer Prevention Trials (APT) Webstudy today. The APT Webstudy aims to identify participants who may be good future candidates for AHEAD 3-45. Information on how to register for the APT Webstudy can be found just below.
Those interested can also provide their email address to be alerted when the AHEAD 3-45 Study is enrolling participants.
The Alzheimer Prevention Trials (APT) Webstudy is an online memory and thinking research tool aimed at accelerating enrollment for Alzheimer’s clinical trials by identifying and tracking individuals who may be at higher risk for developing Alzheimer's disease.
The APT Webstudy is being conducted by the University of Southern California Alzheimer's Therapeutic Research Institute (USC ATRI) and funded by the National Institute on Aging (NIA).
AHEAD 3-45 is a public-private partnership with funding from the NIH and Eisai, led by three academic principal investigators: Dr. Paul Aisen from University of Southern California, and Drs. Reisa Sperling and Keith Johnson from Brigham and Women’s Hospital and Massachusetts General Hospital, Harvard Medical School, in partnership with Eisai.
The A3 Study aims to get closer to primary prevention of AD, through preventing amyloid build-up in the brain. The study targets cognitively normal individuals who are currently below the threshold for amyloid elevation on amyloid PET but are at high risk for further Aβ accumulation. The A3 Study is a global, multicenter, double-blind, randomized trial to compare the effects of low dose BAN-2401 vs. placebo, to test whether an anti-amyloid beta antibody targeted at protofibrils can slow brain amyloid accumulation at this very early stage of disease. The A3 Study also measures accumulation of tangle pathology using tau PET and exploratory cognitive outcomes.
The A45 Study targets the preclinical (pre-symptomatic) stage of AD. The study will enroll clinically normal participants (little to no cognitive impairment) who have elevated levels of amyloid in brain and are at high risk for progression to mild cognitive impairment and AD dementia. The A45 Study is a global, multicenter, double-blinded, placebo-controlled, randomized trial of a treatment regimen consisting of an anti-amyloid beta antibody targeted at protofibrils to prevent cognitive decline and delay biomarkers of pathological progression versus placebo. In the active arm, individuals will be treated with high-dose BAN2401 to clear amyloid deposits and Aβ protofibrils from the brain, followed by low-dose BAN2401 to prevent re-accumulation of amyloid. The aim of this study is to slow or prevent decline in cognitive performance.
The ACTC is an NIA-funded clinical trial network with 35 primary clinical study sites across the United States, with aims to accelerate and expand studies for therapies in AD and related dementias across the spectrum from pre-symptomatic to more severe stages of disease.
Visit actcinfo.org for more information